[Form 4] Stoke Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Jonathan Allan, General Counsel and Corporate Secretary of Stoke Therapeutics, Inc. (STOK), reported a transaction on 08/18/2025 selling 1,683 shares of the company's common stock. The filing states this was an issuer-mandated sale to satisfy tax withholding liabilities arising from the vesting and settlement of restricted stock units. The weighted-average proceeds reported were $18.238 per share (sales occurred at prices ranging from $18.00 to $18.50). After the sale, Mr. Allan beneficially owned 23,948 shares. The form is a routine Section 16 disclosure showing an internal tax-related disposition rather than a voluntary market-timed sale.

Positive

• Timely and clear disclosure of the insider transaction in accordance with Section 16 requirements
• Transaction explicitly described as issuer-mandated to satisfy tax withholding from RSU vesting, reducing ambiguity

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: Routine, compliance-driven insider sale to cover taxes; no new governance concerns evident.

This Form 4 documents a mandated sale to satisfy tax withholding on vested restricted stock units, a common administrative transaction. The reporting person is an officer and director, which makes transparency important; timely filing and clear explanation align with good governance practices. The transaction size (1,683 shares) and remaining beneficial ownership (23,948 shares) do not appear to indicate a change in insider control or a material shift in alignment with shareholders.

Securities Analyst

TL;DR: Administrative disposition with negligible market impact; disclosure is standard.

The sale was disclosed as issuer-mandated for tax withholding tied to RSU settlement and reported at a weighted-average price of $18.238, with trades ranging $18.00 to $18.50. The size of the sale relative to the reporter's post-transaction holdings suggests this was a mechanical tax-related event rather than a signal about company fundamentals. No derivative transactions or additional dispositions are reported.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Allan Jonathan

(Last) (First) (Middle)

C/O STOKE THERAPEUTICS, INC.

45 WIGGINS AVENUE

(Street)

BEDFORD MA 01730

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Stoke Therapeutics, Inc. [ STOK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	GENERAL COUNSEL & CORP SEC

3. Date of Earliest Transaction (Month/Day/Year)
08/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/18/2025		S(1)		1,683	D	$18.238(2)	23,948	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.50 per share, inclusive.

	/s/ Jonathan Allan	08/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Jonathan Allan report on Form 4 for STOK?

He reported an issuer-mandated sale of 1,683 common shares on 08/18/2025 to cover tax withholding from vested RSUs.

At what price were the STOK shares sold in the Form 4 transaction?

The filing reports a weighted-average price of $18.238 per share, with individual sale prices ranging from $18.00 to $18.50.

How many STOK shares does Jonathan Allan own after the reported sale?

Following the sale, he beneficially owns 23,948 shares.

Why were the STOK shares sold according to the filing?

The shares were sold to satisfy tax withholding liabilities associated with the vesting and settlement of restricted stock units.

What is Jonathan Allan's role at Stoke Therapeutics (STOK)?

He is listed as General Counsel & Corporate Secretary and is also identified as an officer and director.